NCT03195699: Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 65 Years (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active metastases in the central nervous system- see trial for details

Comments are closed.

Up ↑